SecBot SecBot
PRESS-RELEASE ·Filed May 11, 2026

SANA

Sana Biotechnology, Inc
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss and continued cash burn are negative, but the Mayo collaboration and pipeline catalysts (SC451 IND, SG293 data) could drive near-term volatility. Watch for IND filing updates and ASGCT presentation on May 12 for SG293 surrogate data, positive results could reverse sentiment. Cash runway into 2027 reduces near-term dilution risk.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.26
T+0 close · May 11, 2026 · via day close
Latest settled
+4.60%
T+60 · $3.41
Vs SPY
+0.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $3.26entry
  2. T+1 · 6mo ago 0.00%α −0.54% · $3.26
  3. T+5 · 6mo ago −6.75%α −6.83% · $3.04
  4. T+20 · 5mo ago −13.50%α −11.77% · $2.82
  5. T+60 · 3mo ago +4.60%α +0.22% · $3.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share, slightly better than the $0.21 loss in Q1 2025 but worse than the $0.15 consensus estimate. The company highlighted progress toward clinical trials for SC451 (type 1 diabetes) and SG293 (non-Hodgkin lymphoma), a strategic collaboration with Mayo Clinic including a $25M equity investment, and a cash runway into 2027. The EPS miss and lack of revenue are bearish, but the pipeline progress and collaboration provide some offset.

Key Financial Metrics

EPS
−$0.17
est −$0.15 · -13.3%
Rating
miss

Key Facts

  • GAAP net loss per share of $0.17 vs consensus estimate of $0.15 (miss of 13.3%)
  • Net loss of $47.2M in Q1 2026 vs $49.4M in Q1 2025
  • Cash, cash equivalents, and marketable securities of $101.1M as of March 31, 2026, down from $138.4M at year-end 2025
  • Non-GAAP operating cash burn of $37.0M in Q1 2026 vs $46.6M in Q1 2025
  • Entered strategic collaboration with Mayo Clinic for SC451, including $25M equity investment with option for additional $25M
  • Reported positive 14-month clinical data for UP421 (HIP-modified islet cells) showing ongoing survival and function without immunosuppression
  • Expects to file IND and begin Phase 1 trial for SC451 later in 2026
  • Expects to begin clinical study for SG293 (in vivo CAR T) later in 2026
  • Appointed Brian Piper as new CFO
  • No revenue reported; pre-revenue biotechnology company

Financial Impact

EPS miss of $0.02 vs consensus; cash burn of $37M in the quarter; cash runway into 2027

epscashnetLoss

Risk Factors

  • Clinical trial delays or failures for SC451 or SG293
  • Continued cash burn without near-term revenue
  • Dilution risk from ATM facility and potential future equity offerings
  • Dependence on Mayo Clinic collaboration for SC451 development

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
87% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292311

Track record

12 reports on SANA

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.93% at T+60 after the Apr 13, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
  3. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  4. Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
  5. May 11, 202627w ago 8-K Neutral 4/10 No price data
  6. May 11, 202627w ago Press Release Bearish 6/10 Viewing Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  8. Apr 24, 202629w ago 8-K Neutral 2/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
  9. Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
  10. Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026